Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (26/120, 21.6 %), penicillin (11/71, 15.4 %) and metronidazole (14/131, 10.7 %). In conclusion, C. perfringens reduced susceptibility phenotype to first-line therapy.
A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY) / Geremia, N., Sanson, G., Principe, L., Antonello, R.M., Zerbato, V., Luzzati, R., ITANAEROBY study, G., Maraolo, A.E., Giacobbe, D.R., Sepulcri, C., Ambretti, S., Aschbacher, R., Bartolini, L., Bernardo, M., Bielli, A., Busetti, M., Carcione, D., Camarlinghi, G., Carretto, E., Cassetti, T., et al.. - In: ANAEROBE. - ISSN 1075-9964. - ELETTRONICO. - 90:(2024), pp. 102901."-"-102901."-". [10.1016/j.anaerobe.2024.102901]
A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY)
Sanson, GianfrancoSecondo
;Antonello, Roberta Maria;Zerbato, Verena;Luzzati, RobertoPenultimo
;Busetti, MarinaMembro del Collaboration Group
;Di Bella, StefanoMembro del Collaboration Group
2024-01-01
Abstract
Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (26/120, 21.6 %), penicillin (11/71, 15.4 %) and metronidazole (14/131, 10.7 %). In conclusion, C. perfringens reduced susceptibility phenotype to first-line therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
GEREMIA A 2024 C perfringens.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
434.4 kB
Formato
Adobe PDF
|
434.4 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
